|View printer-friendly version|
Portola Pharmaceuticals Announces Executive Leadership Change
The Company has engaged a leading executive search firm to assist management in identifying and recruiting a new chief commercial officer in parallel with the Company’s search for a chief executive officer. During the transition period,
“On behalf of the entire management team, I’d like to thank Tao for his many contributions during a critical period in Portola’s evolution,” said Ms. Dier. “Tao led two nearly simultaneous U.S. product launches and played an integral role in our transition from an R&D organization into a commercial company. We are grateful for his many contributions and wish him all the best in future endeavors.”
Ms. Dier added: “During this transitional period, our top priority remains the Andexxa Early Supply Program, which we launched in May and is continuing to gain momentum, and we are implementing a focused commercial strategy for Bevyxxa. Additionally, we are looking forward to a number of significant regulatory milestones that will drive the Company’s long-term growth, including the potential U.S. regulatory approval of the large-scale Generation 2 Andexxa manufacturing process, European approval of andexanet alfa, and the potential regulatory path forward for cerdulatinib, our Syk/JAK inhibitor and the third novel compound discovered in our labs.”
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.